Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

The expansion of the EU has created exciting opportunities for pharmaceutical companies to expand into new territories and take advantage of these high growth emerging markets; this report analyzes eight of the accession countries including the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia (The A8). Pharmaceutical Growth Opportunities in the EU Accession States is a new report which provides in-depth insights into the competitive dynamics of the EU accession states. It identifies the key drivers and resistors of growth to enable you to understand the most important factors behind success in each country market. Use this latest report to determine key product opportunities, identify potential alliance partners and plan a successful and sustainable long term growth strategy to secure your leading position in the next five years.

Table of Contents
Pharmaceutical Growth Opportunities in the EU
Accession States
Executive Summary 10
The external environment in the accession states 10
The market opportunity in the accession states 11
Market composition in the accession states 12
Competitive dynamics in the accession pharmaceutical markets 13
Chapter 1 The external environment in the
accession states 16
Summary 16
Introduction 17
Background 19
Healthcare systems in the accession states 20
Healthcare financing in the accession states 20
Private and public sources of healthcare financing 23
Structural challenges to pharmaceutical marketers in the accession states 25
Healthcare delivery 26
Social aspects 28
Market factors 28
Pricing and reimbursement 29
Healthcare reform in the accession countries 30
EU pharmaceutical policy and its implications for accession markets 32
EU competition law 32
Intellectual property rights 33
Marketing approvals 35
Parallel importing and pricing issues 36
Profiles of healthcare systems across the accession states 38
Czech Republic 38
Poland 43
Slovenia 47
Slovakia 51
iv
Latvia 55
Lithuania 60
Estonia 62
Hungary 66
Road to reform in the accession states 70
Chapter 2 The market opportunity in the
accession states 74
Summary 74
Introduction 75
Market dynamics in the accession states 75
Breakdown of market composition by therapeutic areas 77
Market breakdown by therapeutic areas over the period 2000-04: a
comparison between A8 and EU5 80
Key trends in the accession pharmaceutical markets: therapeutic class specific
analysis 82
Cardiovascular 82
Cardiovascular market analysis 82
Analysis of cardiovascular sales by country, 2000-04 85
Key growth drivers in the cardiovascular market 86
CNS 88
CNS market analysis 88
Analysis of CNS sales by country, 2000-04 90
Key growth drivers in the CNS market 91
Respiratory 92
Respiratory market analysis 93
Analysis of respiratory sales by country, 2000-04 94
Key growth drivers in the respiratory market 95
Anti-infectives 96
Anti-infectives market analysis 96
Analysis of anti-infectives sales by country, 2000-04 98
Key growth drivers in the anti-infectives market 99
Cancer 99
Cancer market analysis 99
Analysis of cancer sales by country, 2000-2004 102
Key growth drivers in the cancer market 103
Others 104
Analysis of sales across other therapeutic areas in the accession
countries, 2000-04 104
Sales forecasts in the accession pharmaceutical market by therapeutic area 105
v
Chapter 3 Market composition in the
accession states 110
Summary 110
Introduction 111
Licensing trends: a comparison with the EU5 112
The A8 113
The EU5 117
Current licensing trends 118
Licensing trends in the accession states 120
Other brands 120
Original brands 122
Licensed brands 125
Unbranded drugs 127
Therapeutic licensing trends in the accession states 128
Cardiovascular 131
CNS 133
Cancer 134
Anti-infectives 135
Respiratory 137
Other therapeutic areas 138
Future licensing trends 140
Chapter 4 Competitive dynamics in the
accession pharmaceutical markets 144
Summary 144
Introduction 145
Analysis of the major pharmaceutical players in the accession states 146
Overview of the performance of major companies in the accession region 146
Strategies for success in the accession pharmaceutical market 151
Key regional players 151
Zentiva 151
Gedeon Richter 155
KRKA 161
Polpharma 164
Pliva 167
Key multinational players 171
Novartis 171
Sanofi-Aventis 174
GlaxoSmithKline 178
Servier 181
Pfizer 184
vi
Winning strategies in the accession pharmaceutical market 187
Competitive strategy of key regional players in the accession
pharmaceutical market 189
Competitive strategy of key multinational players in the accession
pharmaceutical market 190
Strategies for companies to succeed within the top therapeutic areas 191
Chapter 5 Appendix 194
Glossary 194
Index 197
List of Figures
Figure 1.1: Average total health expenditure as a proportion of GDP for EU5 and A8 regions,
2000-04 21
Figure 1.2: Structural challenges shaping A8 market development 25
Figure 1.3: Structural challenges in healthcare delivery in the A8 region 27
Figure 1.4: Major challenges in healthcare reform across the A8 region 31
Figure 1.5: Average total health expenditure as % of GDP for the Czech Republic, the A8 and the
EU5, 2000-04 39
Figure 1.6: Direct personal expenditure of individuals on health services in the Czech Republic,
2000-04 40
Figure 1.7: Cash expenditure on healthcare paid directly by individuals in the Czech Republic,
2004 41
Figure 1.8: Average total health expenditure as % of GDP for Poland, the A8 and the EU5, 2000-
04 44
Figure 1.9: Average total health expenditure as % of GDP for Slovenia, the A8 and the EU5,
2000-04 47
Figure 1.10: Average total health expenditure as % of GDP for Slovakia, the A8 and the EU5,
2000-04 51
Figure 1.11: Average total health expenditure as % of GDP for Latvia, the A8 and the EU5, 2000-
04 55
Figure 1.12: Average total health expenditure as % of GDP for Lithuania, the A8 and the EU5,
2000-04 60
Figure 1.13: Average total health expenditure as % of GDP for Estonia, the A8 and the EU5, 2000-
04 63
Figure 1.14: Total health expenditure as % of GDP for Hungary, the A8 and the EU5, 2000-04 66
Figure 1.15: Historic and present challenges in healthcare reform in the A8 71
Figure 2.16: Forecast A8 market composition by therapy area, 2004 and 2011 107
Figure 3.17: Comparison of sales in the A8 and the EU5 by product category, 2004 118
Figure 3.18: Comparison of sales in the A8 pharmaceutical markets by product category, 2004 120
Figure 3.19: Comparison of licensing sales in the A8 pharmaceutical markets, 2004 130
Figure 4.20: Breakdown of the leading pharmaceutical companies in the A8, 2004 145
Figure 4.21: Growth dynamics of the leading pharmaceutical companies in the A8, 2004 149
Figure 4.22: Outlook for leading pharmaceutical companies in the A8 region, 2005-11 188
vii
List of Tables
Table 1.1: Recent statistics on healthcare sector in the A8 markets, 2004 22
Table 1.2: Public and private healthcare financing in the A8 markets, 2004 23
Table 1.3: Summary of pricing and reimbursement policies across the A8 markets 29
Table 1.4: Healthcare resources in the Czech Republic, the A8 and EU5 countries, 2004 42
Table 1.5: Healthcare resources in Poland, the A8 and EU5 countries, 2004 45
Table 1.6: Estimation of expenses for healthcare services in Slovenia, 2000-03 48
Table 1.7: Healthcare resources in Slovenia, the A8 and EU5 countries, 2004 49
Table 1.8: Healthcare resources in Slovakia, the A8 and EU5 countries, 2004 53
Table 1.9: Healthcare resources in Latvia, the A8 and EU5 countries, 2004 57
Table 1.10: Healthcare resources in Lithuania, the A8 and EU5 countries, 2004 61
Table 1.11: Healthcare resources in Estonia, the A8 and EU5 countries, 2004 65
Table 1.12: Healthcare resources in Hungary, the A8 and EU5 countries, 2004 68
Table 2.13: Pharmaceutical market dynamics across the A8 countries, 2000-04 76
Table 2.14: Breakdown of sales by therapeutic areas across the EU5 and A8 markets, 2004 78
Table 2.15: Breakdown of sales by major therapeutic area across EU5, 2000–04 80
Table 2.16: Breakdown of sales by major therapeutic area across A8, 2000–04 81
Table 2.17: Sales by major classes across the cardiovascular market in the A8 countries, 2000–04
83
Table 2.18: Sales by A8 country in the cardiovascular market, 2000 and 2004 85
Table 2.19: Sales by major classes across the CNS market in the A8 countries, 2000–04 88
Table 2.20: Sales by A8 country in the CNS market, 2000 and 2004 90
Table 2.21: Sales by major classes across the respiratory market in the A8 countries, 2000–04 93
Table 2.22: Sales by A8 country in the respiratory market, 2000 and 2004 94
Table 2.23: Sales by major classes across the anti-infectives market in the A8 countries, 2000–04
96
Table 2.24: Sales by A8 country in the anti-infectives market, 2000-2004 98
Table 2.25: Sales by major classes across the cancer market in the A8 countries, 2000–04 100
Table 2.26: Sales by A8 country in the cancer market, 2000-2004 102
Table 2.27: Sales of other therapeutic categories in the A8 countries, 2000-04 105
Table 2.28: Sales forecasts for key therapeutic areas in the A8 market, 2004–11 106
Table 3.29: Sales in the A8 and EU5 pharmaceutical markets by product category, 2000-04 112
Table 3.30: Sales in the A8 pharmaceutical markets by product category, 2000-04 114
Table 3.31: Sales in the A8 pharmaceutical markets by product category, 2000-04 (cont.) 115
Table 3.32: Sales of other brands in the A8 pharmaceutical markets, 2000-04 121
Table 3.33: Sales of original brands in the A8 pharmaceutical markets, 2000-04 123
Table 3.34: Sales of licensed brands in the A8 pharmaceutical markets, 2000-04 125
Table 3.35: Sales of unbranded drugs in the A8 pharmaceutical markets, 2000-04 127
Table 3.36: Therapeutic sales in the A8 pharmaceutical markets by product category, 2004 128
Table 3.37: Sales of cardiovascular therapeutics in the A8 pharmaceutical markets by product
category, 2004 132
Table 3.38: Sales of CNS therapeutics in the A8 pharmaceutical markets by product category,
2004 133
Table 3.39: Sales of cancer therapeutics in the A8 pharmaceutical markets by product category,
2004 135
Table 3.40: Sales of anti-infective therapeutics in the A8 pharmaceutical markets by product
category, 2004 136
viii
Table 3.41: Sales of respiratory therapeutics in the A8 pharmaceutical markets by product
category, 2004 137
Table 3.42: Sales of other therapeutics in the A8 pharmaceutical markets by product category,
2004 139
Table 4.43: Sales of leading pharmaceutical companies in the A8 region, 147
Table 4.44: Zentiva’s sales in the A8 pharmaceutical markets, 2000-04 153
Table 4.45: Zentiva’s corporate agreements, 2003-2006 154
Table 4.46: Gedeon Richter’s sales in the A8 pharmaceutical markets, 2000-04 157
Table 4.47: Gedeon Richter’s corporate agreements, 2000-2006 158
Table 4.48: KRKA’s sales in the A8 pharmaceutical markets, 2000-04 162
Table 4.49: KRKA’s corporate agreements, 2000-2006 162
Table 4.50: Polpharma’s sales in the A8 pharmaceutical markets, 2000-04 165
Table 4.51: Polpharma’s corporate agreements, 2000-2006 165
Table 4.52: Pliva’s sales in the A8 pharmaceutical markets, 2000-04 168
Table 4.53: Pliva’s corporate agreements, 2000-2006 169
Table 4.54: Novartis’ sales in the A8 pharmaceutical markets, 2000-04 172
Table 4.55: Novartis’ corporate agreements, 2000-2006 174
Table 4.56: Sanofi-Aventis’ sales in the A8 pharmaceutical markets, 2000-04 175
Table 4.57: Sanofi-Aventis’ corporate agreements, 2000-2006 177
Table 4.58: GSK’s sales in the A8 pharmaceutical markets, 2000-04 178
Table 4.59: GSK’s corporate agreements, 2000-2006 180
Table 4.60: Servier’s sales in the A8 pharmaceutical markets, 2000-04 182
Table 4.61: Servier’s corporate agreements, 2000-2006 184
Table 4.62: Pfizer’s sales in the A8 pharmaceutical markets, 2000-04 185